In a report released today, Andrew Mok CFA from Barclays maintained a Buy rating on Universal Health, with a price target of $250.00. The company’s shares closed yesterday at $205.20.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Mok CFA is an analyst with an average return of -1.9% and a 51.69% success rate. Mok CFA covers the Healthcare sector, focusing on stocks such as HCA Healthcare, Humana, and UnitedHealth.
In addition to Barclays, Universal Health also received a Buy from Wells Fargo’s Stephen Baxter in a report issued on October 7. However, on the same day, Cantor Fitzgerald reiterated a Hold rating on Universal Health (NYSE: UHS).
Based on Universal Health’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $4.28 billion and a net profit of $353.22 million. In comparison, last year the company earned a revenue of $3.91 billion and had a net profit of $289.15 million
Read More on UHS:
Disclaimer & DisclosureReport an Issue
- Universal Health price target raised to $249 from $210 at Wells Fargo
- Universal Health Faces $500 Million Verdict in Nevada
- Universal Health price target lowered to $250 from $259 at Barclays
- Ex-Dividend Date Nearing for These 10 Stocks – Week of September 1, 2025
- Universal Health price target raised to $206 from $201 at RBC Capital
/Pfizer%20Inc_%20logo%20sign-by%20JHVEPhoto%20via%20iStock.jpg)
/Netflix%20on%20tv%20with%20remote%20by%20freestocks%20via%20Unsplash.jpg)
